RecruitingNCT06534489

Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment

Studying NON RARE IN EUROPE: Non-small cell lung cancer

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ruijin Hospital
Intervention
neoadjuvant immuno-chemotherapy and surgery(procedure)
Enrollment
50 target
Eligibility
18-75 years · All sexes
Timeline
20232029

Study locations (1)

Collaborators

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Huadong Hospital · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06534489 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Non-small cell lung cancer

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Non-small cell lung cancer

← Back to all trials